Solid Dosage Forms Of Bendamustine

Abstract

In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.

1 . A pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the ratio by weight of the active ingredient to the saccharide is 1:2-5. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , which is in the form of a tablet, a granulate, or a pill. 
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein the tablet or tablet granules of the tablet, the granulate or the pill are provided with a coating. 
     
     
         5 . The pharmaceutical composition according to  claim 1 , wherein the active ingredient is bendamustine hydrochloride. 
     
     
         6 . The pharmaceutical composition according to  claim 1 , which comprises 10 to 1000 mg of the active ingredient and 30 to 5000 mg of the saccharide excipient. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , wherein the saccharide excipient is selected from mannitol, maltitol, erythritol, xylitol, lactose, sucrose, glucose, sorbitol, maltose, trehalose, lactitol, dextrose and fructose. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , wherein the saccharide excipient is selected from dextrose anhydrous, dextrose monohydrate, lactitol monohydrate, trehalose, sorbitol, erythritol, maltose monohydrate, mannitol, lactose anhydrous, lactose monohydrate, maltitol, xylitol, sucrose, sucrose 97%+maltodextrin 3%, β-cyclodextrin, D-raffinose pentahydrate, D-melezitose monohydrate and microcrystalline cellulose. 
     
     
         9 . The pharmaceutical composition according to  claim 1 , which further comprises a pharmaceutically acceptable lubricant, filler and/or disintegrant. 
     
     
         10 . A pharmaceutical composition according to  claim 1 , wherein the composition undergoes dissolution of the bendamustine of at least 60% in 10 minutes, 70% in 20 minutes and 80% in 30 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. 
     
     
         11 . A method of treating a disease in a human comprising administering an effective amount of the composition according to  claim 1 , wherein the disease is chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovary cancer, small cell lung cancer, non-small cell lung cancer, and or an autoimmune disease. 
     
     
         12 . The method according to  claim 11 , wherein the composition is administered in combination with at least one additional active agent, wherein said additional active agent is administered prior, concurrently, or subsequently to the administration of the pharmaceutical composition. 
     
     
         13 . The method according to  claim 12 , wherein the additional active agent is an antibody specific for CD20, an anthracyclin derivative, a vinca alkaloid or a platin derivative. 
     
     
         14 . The method according to  claim 13 , wherein the antibody specific for CD20 is rituximab, wherein the anthracyclin derivative is doxorubicin or daunorubicin, wherein the vinca alkaloid is vincristine and wherein the platin derivative is cisplatin or carboplatin. 
     
     
         15 . The method according to  claim 11 , wherein the administration is in combination with at least one corticosteroid, wherein said corticosteroid is given prior, concurrently, or subsequently to the administration of the pharmaceutical composition 
     
     
         16 . The method according to  claim 15 , wherein the corticosteroid is prednisone or prednisolone.